Salud financiera de hoja de balance de Sun Pharmaceutical Industries
Salud financiera controles de criterios 6/6
Sun Pharmaceutical Industries tiene un patrimonio de accionistas total de ₹693.8B y una deuda total de ₹20.8B, lo que sitúa su ratio deuda-patrimonio en 3%. Sus activos y pasivos totales son ₹881.2B y ₹187.4B respectivamente. El BAIT de Sun Pharmaceutical Industries es de ₹114.5B, por lo que su ratio de cobertura de intereses es de -12.9. Tiene efectivo e inversiones a corto plazo que ascienden a ₹201.2B.
Información clave
3.0%
Ratio deuda-patrimonio
₹20.81b
Deuda
| Ratio de cobertura de intereses | -12.9x |
| Efectivo | ₹201.22b |
| Patrimonio | ₹693.80b |
| Total pasivo | ₹187.36b |
| Activos totales | ₹881.16b |
Actualizaciones recientes sobre salud financiera
Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Nov 18
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Jun 12Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Recent updates
Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Nov 18Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Oct 31We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease
Oct 21Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now
Aug 24Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Aug 06This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid
Jul 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth
Jun 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Jun 12Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 25Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings
May 22Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 03Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Jan 05Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely
Dec 18Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Oct 04Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jul 03We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50
Feb 03These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?
Oct 13These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Aug 05Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (₹461.1B) de SUNPHARMA superan a sus pasivos a corto plazo (₹172.6B).
Pasivo a largo plazo: Los activos a corto plazo de SUNPHARMA (₹461.1B) superan a sus pasivos a largo plazo (₹14.8B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: SUNPHARMA tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de SUNPHARMA ha pasado de 15.9% a 3% en los últimos 5 años.
Cobertura de la deuda: La deuda de SUNPHARMA está bien cubierta por el flujo de caja operativo (611%).
Cobertura de intereses: SUNPHARMA gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.